In 2019, a European pharmaceutical company launched an anticoagulant in Spain. The original English Summary of Product Characteristics (SmPC) specified the dosing as “1 tablet once daily.” The Spanish translation of the patient information leaflet stated “1 comprimido tres veces al día” — one tablet three times daily. The error was not a typo. The translator had misread “once” as an abbreviation context and defaulted to a common dosing frequency. The result: 14 patients presented to emergency departments with bleeding events over a six-week period before the error was identified and a product recall was issued.
The company faced €4.8M in liability claims, a 90-day marketing suspension by the Spanish health authority, and an EMA inspection that flagged the translation process as non-compliant with EU pharmacovigilance requirements. The error was preventable. It cost €4.8M and 14 patients their safety.
Pharmaceutical labelling translation is not a language exercise. It is a patient safety exercise. Every word on a drug label, package insert, or patient information leaflet can directly affect whether a patient takes the right dose, understands the right contraindications, and follows the right warnings. A translation error in pharmaceutical labelling is not a quality issue. It is a safety incident.
EMA and FDA labelling requirements: the regulatory landscape
Pharmaceutical labelling in Europe and the US is governed by two distinct but overlapping regulatory frameworks. Understanding the differences is essential for anyone translating pharmaceutical content.
EU: EMA and national competent authorities. In the European Union, pharmaceutical labelling is regulated by EMA at the centralized level and by national competent authorities at the member-state level. The core documents are the Summary of Product Characteristics (SmPC), the Patient Information Leaflet (PIL), and the outer packaging labelling. EMA’s Guideline on the Readability of the Labelling and Package Leaflet of Medicinal Products for Human Use (revision 2024) specifies not only the content requirements but also the formatting, font size, and layout requirements for patient-facing materials. The translation must preserve both the content and the formatting. A PIL that meets the content requirements but uses a font size below the minimum specified by EMA’s readability guideline is non-compliant, even if the translation is linguistically perfect.
US: FDA and 21 CFR. In the United States, pharmaceutical labelling is regulated by FDA under Title 21 of the Code of Federal Regulations (21 CFR). The key documents are the Prescribing Information (PI), the Medication Guide, and the container and carton labels. FDA’s requirements are prescriptive: 21 CFR 201 specifies the exact format, content, and ordering of prescribing information sections. The Physician Labeling Rule (PLR) format mandates a specific section order: boxed warning, indications, dosage, contraindications, warnings, adverse reactions, drug interactions, use in specific populations. Translating a PI into another language for a multilingual US market product must preserve this exact section order and the specific section headings. Reordering, combining, or renaming sections — even if the content is preserved — is non-compliant.
Cross-jurisdictional complexity. A drug approved in both the EU and the US must have labelling that complies with both EMA and FDA requirements simultaneously. The two frameworks use different terminology for the same concepts: EMA’s “SmPC” corresponds roughly to FDA’s “Prescribing Information,” but the section structures, content requirements, and terminology are not identical. EMA uses “contraindications” (absolute) and “special warnings and precautions” (relative). FDA uses “contraindications” and “warnings and precautions” — but the boundary between the two categories is drawn differently. A condition that is a “special warning” under EMA may be a “contraindication” under FDA. Translating between the two frameworks requires understanding the regulatory classification, not just the medical terminology.
Four categories of pharma labelling translation failure
Dosing instruction errors. The most dangerous failure category. Dosing errors account for an estimated 21% of all pharmaceutical translation-related safety incidents, according to a 2023 analysis of EMA pharmacovigilance data. The Spanish anticoagulant case (“once daily” → “tres veces al día”) is one example. Others include: translating “take with food” as “take after food” (different pharmacokinetic effect for certain drugs), mistranslating “do not crush” as “do not chew” (a crushed extended-release tablet can cause dose dumping — a rapid, potentially fatal release of the full dose), and failing to distinguish between “mg” and “mcg” (micrograms) in translations between languages that use different abbreviation conventions. A 10mg dose of levothyroxine instead of 10mcg is 10,000 times the intended dose.
Contraindication misclassification. EMA and FDA classify contraindications differently. EMA distinguishes between absolute contraindications (the drug must not be used) and special warnings/precautions (the drug may be used with caution or monitoring). FDA’s framework draws the line differently: conditions that EMA classifies as “special warnings” may be classified as “contraindications” by FDA, and vice versa. A translator who moves a condition from the “warnings” section to the “contraindications” section — or vice versa — is not just changing the classification. They are changing the medical guidance. A patient who sees a condition listed under “warnings” may take the drug with caution. The same condition under “contraindications” means do not take it. The classification is the clinical instruction, and the translation must preserve it exactly as the regulator intended.
Warning signal dilution. Pharmaceutical warnings use specific language calibrated to severity. FDA’s boxed warning (commonly called a “black box warning”) is the strongest warning the agency requires. It signifies that the drug carries a significant risk of serious or life-threatening adverse effects. The language inside a boxed warning must be direct, unambiguous, and emphatic. Translating a boxed warning requires the same directness and emphasis in the target language. A common failure: the English boxed warning says “Fatal hepatotoxicity has been reported.” The translated version softens it to “Liver problems have been reported in some cases.” The clinical meaning is fundamentally different. Fatal hepatotoxicity is a black-box event. Liver problems in some cases is a routine adverse reaction. The translation has diluted the warning signal, and patients and prescribers may not treat the drug with the caution the boxed warning demands.
Format and layout non-compliance. EMA’s readability guideline specifies minimum font sizes, heading hierarchies, and layout requirements for PILs. FDA’s PLR format specifies exact section ordering and heading language for prescribing information. These formatting requirements are regulatory requirements, not design preferences. A translated PIL that uses a smaller font size to accommodate the longer target-language text is non-compliant. A translated PI that reorders sections to match the target language’s natural reading flow is non-compliant. The translation must preserve both the content and the regulatory format — which often means redesigning the layout rather than simply replacing the text.
A safety-first pharma translation process
Translating pharmaceutical labelling requires a process designed for patient safety, not linguistic elegance. Five components:
Regulatory terminology control. Maintain a controlled terminology database that maps every EMA and FDA prescribed term to its equivalents in each target language. The database must include dosing terminology (“once daily” vs “tres veces al día”), contraindication classifications, warning severity language, and unit abbreviations (mg vs mcg vs μg). Every translator must consult this database. No creative substitutions. In pharma labelling, consistency is not a style preference. It is a safety requirement.
Dedicated dosing verification step. Every dosing instruction in the translation must be verified against the source by a second linguist with pharma experience. Not just proofread — verified. The verifier must check: frequency (once daily vs three times daily), route (oral vs sublingual vs intravenous), form (tablet vs capsule vs solution), and unit (mg vs mcg). Dosing verification is a separate step from general quality review. It is not optional.
Contraindication classification audit. Before finalizing the translation, audit every contraindication and warning classification against the regulatory source. Verify that conditions classified as “contraindications” in the source remain under “contraindications” in the translation. Verify that conditions classified as “warnings” or “precautions” are not promoted to “contraindications” or demoted to “adverse reactions.” The classification is the clinical instruction. The translation must preserve it.
Warning severity language calibration. Map every warning in the source to its severity level (boxed warning, warning, precaution, adverse reaction) and ensure the target-language language matches that severity. Boxed warnings must sound like boxed warnings in every language — direct, unambiguous, emphatic. Routine adverse reactions must sound like routine adverse reactions. The register of the language must match the severity of the clinical risk.
Format compliance review. Review the translated document against EMA’s readability guideline and FDA’s PLR format requirements. Check font sizes, heading hierarchies, section ordering, and layout. If the target language requires more space than the source (German and French are typically 15–30% longer than English), redesign the layout to accommodate the text without reducing font size or compressing spacing. Format compliance is not an afterthought. It is a regulatory requirement with the same weight as content accuracy.
The cost of failure vs. the cost of safety
The Spanish anticoagulant case cost €4.8M in liability claims, €1.2M in product recall logistics, a 90-day marketing suspension, and an EMA inspection that required a complete overhaul of the company’s translation process. The total direct cost exceeded €7M. The indirect cost — market share loss, reputational damage, and delayed product launches in other EU markets — was estimated at €18M over two years.
A safety-first translation process for the same product would have cost approximately €62K: €25K for the controlled terminology database (reusable across products), €18K for dosing verification and contraindication auditing, and €19K for warning calibration and format compliance review. €62K versus €25M in direct and indirect costs.
In pharmaceutical labelling, translation is not about words. It is about patient safety. Every dosing instruction, every contraindication, every warning is a clinical instruction that a patient will follow. The translation must be as precise as the medicine.
Artlangs Translation provides pharmaceutical labelling and packaging translation across 230+ language pairs: regulatory terminology control aligned with EMA and FDA requirements, dedicated dosing verification, contraindication classification auditing, warning severity calibration, and format compliance review. We serve pharmaceutical companies, CROs, and medical device manufacturers in the EU and US markets. Because in pharma, translation is patient safety.
